OSBPL5 Methylation Analysis for NK Cell Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and quantifying natural killer cells, especially in non-peripheral blood samples and suboptimal quality tissues, are inadequate due to issues with cell integrity, antigen specificity, and the lack of robust and quantitative analysis tools, particularly for distinguishing CD56dim and CD56bright NK cells.
Innovation Solution
Analyzing the methylation status and accessibility to bisulfite conversion of CpG positions in the OSBPL5 gene regions, which differentiates CD56dim and CD56bright NK cells by demethylation patterns, allowing for precise identification and quantification independent of sample quality and purification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If flow cytometry is used to identify NK cells based on surface antigen expression, then identification can be performed in peripheral blood, but the method fails in non-peripheral blood samples and suboptimal quality tissues due to cell integrity requirements
Solution Approach 1:
The patent replaces the mechanical/cellular approach of flow cytometry (which requires intact cells with visible surface antigens) with a molecular approach analyzing DNA methylation patterns. This substitution allows identification to proceed at the molecular level even when cells are degraded or from fixed tissues, eliminating the requirement for cell integrity while maintaining identification reliability
Solution Approach 2:
The patent introduces DNA methylation status as an intermediary marker that bridges the gap between cell type identification and sample quality constraints. By using methylation patterns of specific genes (e.g., KIR, NKG7) as the identification marker instead of surface antigens, the method creates an intermediate level of analysis that is insensitive to cell integrity issues
2Measurement precision
If surface antigen expression is used to distinguish NK cell subsets, then CD56 and CD16 markers can be analyzed, but the method lacks robustness in quantifying CD56dim and CD56bright subsets in suboptimal samples
Solution Approach 1:
The patent changes the measurement parameter from surface antigen expression levels (which vary with cell integrity and fixation) to DNA methylation status (which is stable in fixed and frozen tissues). By analyzing the methylation status of specific CpG sites in NK cell-specific genes, the method achieves both precise subset quantification and robustness across different sample qualities
Solution Approach 2:
The patent transitions from analyzing surface protein expression (one dimension: cell membrane level) to analyzing DNA methylation patterns (another dimension: genomic level). This dimensional shift allows measurement of NK cell subsets through a different biological layer that is preserved in suboptimal samples, thereby improving both precision and robustness
3Reliability
If fresh blood samples are used for NK cell analysis, then cell integrity is maintained, but sample collection and analysis timing are constrained
Solution Approach 1:
The patent creates a molecular copy or record of NK cell identity through DNA methylation patterns that can be analyzed later without requiring the original cells to remain intact. The methylation status serves as a stable molecular record that preserves NK cell subset information even when cells are frozen or fixed, eliminating the need for rapid processing of fresh samples
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a robust and quantitative approach for identifying and quantifying NK cells in various samples, including suboptimal quality tissues, with high specificity and accuracy, enabling reliable immune cell analysis and monitoring.
Implementation Method 1
analyzing the accessibility of the genomic DNA for OSBPL, such as OSBPL5, to bisulfite conversion
Data Source
AI summary
The present invention relates to a method, in particular an in vitro method for identifying a subgroup of natural killer cells of a mammal, preferably CD3−, non T-lymphocyte derived NK cells, which often express the surface proteins CD56 and/or CD16, comprising analyzing the accessibility of the genomic DNA for OSBPL, such as OSBPL5, to bisulfite conversion and/or the methylation status of at least one CpG position in the genes for OSBPL, such as OSBPL5, in particular in their upstream and/or downstream regulatory regions, the promoter, introns, exons and introns exon borders and other conserved regions of said genes, wherein an increase of the accessibility of the genomic DNA and/or a demethylation in the sample as analyzed is indicative for said subgroup of NK cells. The analyses according to the invention can identify CD56+ cells and distinguish them from all other cells such as, for example, either CD56− and/or CD56 bright cells. The methods of the present invention are useful for the identification, the detection, the quantification and quality assurance and control of NK cells. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses of the inventive methods or kits. The present invention furthermore provides an improved method for analyzing the accessibility of the genomic DNA for OSBPL, such as OSBPL5, to bisulfite conversion and/or an analysis of the methylation status of at least one CpG position in the genes for OSBPL, such as OSBPL5, allowing for a precise analysis of both optimally and even from sub-optimal quality samples, such as non-freshly obtained blood, tissue or serum samples.